Description

CJC-1295 with DAC is a modified growth hormone-releasing hormone analogue researched for its interaction with growth hormone and related endocrine signalling pathways. The DAC component is associated with an extended biological profile, making this variant relevant to research examining sustained peptide activity and hormone-related signalling. Studies investigate its relationship with growth hormone secretion, IGF-1 pathways, and broader endocrine mechanisms. CJC-1295 has also attracted interest within longevity and metabolic research because of its connection to growth hormone signalling. This formulation contains 10mg across 10 vials and is intended for controlled laboratory research into endocrine pathways, growth hormone signalling, IGF-1 activity, and longevity-related mechanisms.